- Home
- HOLO vs INKT Comparison
HOLO vs INKT Comparison
Compare HOLO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- INKT
- Stock Information
- Founded
- HOLO 2018
- INKT 2017
- Country
- HOLO China
- INKT United States
- Employees
- HOLO N/A
- INKT N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- INKT Medicinal Chemicals and Botanical Products
- Sector
- HOLO Technology
- INKT Health Care
- Exchange
- HOLO Nasdaq
- INKT Nasdaq
- Market Cap
- HOLO 66.3M
- INKT 69.2M
- IPO Year
- HOLO N/A
- INKT 2021
- Fundamental
- Price
- HOLO $4.93
- INKT $14.78
- Analyst Decision
- HOLO
- INKT Buy
- Analyst Count
- HOLO 0
- INKT 3
- Target Price
- HOLO N/A
- INKT $37.50
- AVG Volume (30 Days)
- HOLO 3.1M
- INKT 40.3K
- Earning Date
- HOLO 01-01-0001
- INKT 11-13-2025
- Dividend Yield
- HOLO N/A
- INKT N/A
- EPS Growth
- HOLO N/A
- INKT N/A
- EPS
- HOLO 13.81
- INKT N/A
- Revenue
- HOLO $44,840,587.00
- INKT N/A
- Revenue This Year
- HOLO N/A
- INKT N/A
- Revenue Next Year
- HOLO N/A
- INKT N/A
- P/E Ratio
- HOLO $0.37
- INKT N/A
- Revenue Growth
- HOLO 37.10
- INKT N/A
- 52 Week Low
- HOLO $4.16
- INKT $4.56
- 52 Week High
- HOLO $370.00
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- HOLO 47.61
- INKT 51.12
- Support Level
- HOLO $4.87
- INKT $14.10
- Resistance Level
- HOLO $5.66
- INKT $15.35
- Average True Range (ATR)
- HOLO 0.46
- INKT 1.05
- MACD
- HOLO -0.02
- INKT 0.05
- Stochastic Oscillator
- HOLO 7.55
- INKT 44.12
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.